Dr. Josh Allen to present at 6th Annual Brain Tumor Biotech Summit 2019 in New York, June 7th
Please find all details here.
Events
-
JUN 03 2019
-
-
MAR 21 2019
Abstracts to be Presented at AACR 2019
Oncoceutics, Inc. and its commercial and academic collaborators will be presenting multiple abstracts at the 2019 annual meeting of the American Association for Cancer Research in Atlanta, Georgia, on March 29th to April 3rd. These abstracts will highlight ONC201’s unique mechanism of action, various single agent and combination data, and characterization of other imipridones, including
-
-
NOV 19 2018
ONC201 Advocacy Meeting at SNO 2018 – New Orleans, November 17, 2018
Advocacy Meeting – Oncoceutics, a clinical-stage drug discovery and development company. Looking forward to hearing about what's fresh and new! And who says SNO meetings aren't fun??? Check out THESE faces! 😉 #SNO2018 #endbraincancer pic.twitter.com/uSOUadi3qN — End Brain Cancer Initiative (@EndBrainCancer) November 17, 2018
-
-
JUN 27 2018
Experience with ONC201 in Pediatric High-Grade Gliomas to be presented at ISPNO in Denver, June 30 – July 3, 2018
Two abstracts will be presented at the 2018 International Symposium on Pediatric Neuro-Oncology (ISPNO), Denver, CO, June 30 – July 3. Additional information on the abstracts can be found below: DIPG-54: “Treatment of a pediatric patient with an H3.3 K27M mutant DIPG with ONC201, a selective DRD2 antagonist”. DIPG-42: “Can we change the landscape
-
Business Development
© Copyright 2016 Oncoceutics, Inc. All Rights Reserved.